TX-MARY-KAY
10.6.2019 08:02:10 CEST | Business Wire | Press release
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two major global conferences in Europe this month: the 24th World Congress of Dermatology (WCD), June 10–15 in Milan, Italy and the 5th Future of Formulations in Cosmetics Summit, June 19-20, in Dusseldorf, Germany.
Held every four years, the World Congress of Dermatology is the largest dermatology meeting in the world. The WCD’s 2019 theme, “A New Era for Global Dermatology,” was the perfect match for Mary Kay to present its applied science findings and continue the scientific conversation around pollution and skin damage. On June 12, Mary Kay will host a symposium at the event titled “Environmental Stressors and Skin: Beyond UV.”
The symposium will explore the impact of external environmental aggressors on skin health, with a focus on Europe and how antioxidants can help reduce the damaging effects of pollution. Moderated by Michelle Hines, Ph.D., Director, Global Upstream Research & Technology at Mary Kay, the symposium will feature two renowned European skin experts:
- Jean Krutmann , M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
The extent of air pollution’s impact on skin and overall health was recently revealed in a new comprehensive global review by the Forum of International Respiratory Societies’ Environmental Committee, that reported air pollution may potentially affect every organ in the human body.* The report is especially relevant to the European region, as many European cities have been found to exceed air pollution limits set by the World Health Organization (WHO) or the European Environment Agency (EEA).
In fact, more than 40 towns and cities in the UK alone exceed WHO air pollution limits** and the EEA named 15 cities that are worst affected by dust particle, nitrogen dioxide and sulfur dioxide pollution*** in Germany. Excessive levels of pollution have adverse impact on overall health and are also detrimental to skin health, texture and appearance.
A pioneer of environmental medicine, Professor Krutmann has been relentlessly working in the field of skin protection. “Since I discovered in 2010 that air pollution causes skin aging and skin pigmentation, my institute has conducted a lot of research to verify this observation and to unravel the underlying mechanisms. From these studies it is now clear that long term exposure to traffic-related particulate matter (PM) is not only dangerous for our lungs and cardiovascular system, but skin health is compromised as well,” stated Jean Krutmann, M.D.
Stefanie Williams, M.D., further explained: “We might not be able to separate the damage caused to the skin by UV exposure from those caused by air pollution clinically; however, given the major research advances made in skin and air pollution science, my expectation is that the adverse effects of pollution on skin health will continue to have a growing impact in the future in high-density cities," explained Dr. Williams.
During Mary Kay’s presentation at the 5th Future of Formulations in Cosmetics Summit, Michelle Hines, Ph. D. will reveal Mary Kay’s latest research on an antioxidant complex that helps delay the onset of premature signs of skin aging related to the damaging effects of diesel exhaust particles (DEP). The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Experts have confirmed the significant negative impact of air pollution on skin and this impact will continue to grow as environmental stressors, such as DEP, and pollution levels increase, especially in densely populated urban areas,” Dr. Hines noted. “Mary Kay has discovered targeted technologies that help delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors. Simultaneously, Mary Kay has been advancing scientific discussions with renowned experts around the globe to drive awareness on the negative impact of pollution on skin.”
As one of the world’s leading cosmetics and skincare industry innovators, Mary Kay’s participation in the 24th World Congress of Dermatology and the 5th Future of Formulations in Cosmetics Summit, are the latest installments in a series of global partnerships with the scientific and academic international communities.
Further demonstrating its long-lasting commitment to funding and contributing to skin health research, Mary Kay has also presented research on the topic of skin and pollution in North America at the International Investigative Dermatology meeting in May 2018, in Orlando, Florida, and in Latin America at the Reunion Anual de Dermatologos Latinoamericanos , in May 2019, in Buenos Aires, Argentina.
Every year, Mary Kay invests millions of dollars in research and development, and conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio.
*Review by the Forum of International Respiratory Societies’
Environmental Committee, Part 1: The Damaging Effects of Air Pollution
(February 2019)
** WHO Global Ambient Air Quality Database
(update 2018)
***Report by
Bundesministerium für Umwelt, Naturschutz, Bau und Reaktorsicherheit,
Berlin, Germany. 2015 (Translation: Federal Ministry for Environment,
Nature Conservation, and Nuclear Safety).
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation™, the company has awarded more than $78 million to cancer research and causes to help end domestic violence. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com
About the WCD Meeting
The World Congress of Dermatology (WCD) - is the largest Dermatology meeting in the world. It is held every four years on various continents. The 24th WCD was held in Milano and hosted by the Italian Society of Dermatology (SIDeMaST) from June 10-15, 2019 under the auspices of the International League of Dermatological Societies. It has been over 40 years since Milan last hosted the WCD. The Meeting focused on major breakthroughs and advances in Dermatology, ranging from clinical practice to research, technology and innovation. Learn more at www.wcd2019milan.org
About the 5th Future of Formulations in Cosmetics Summit
The 5th Future of Formulations in Cosmetics Summit brings together senior executives and experts from raw materials and active ingredients manufacturers, chemical companies, major associations, technology companies, brand owners, cosmetic companies, testing companies to discuss the latest changes, challenges and developments within the industry. The 5th Future of Formulations in Cosmetics Summit will be held in Dusseldorf in Germany on June 19-20, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005044/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
